Reflections From BIO International Convention
In June, Boston welcomed more than 20,000 industry professionals to the BIO International Convention. This annual meeting is one of the prime opportunities for biotechs to get in front of a global audience of potential partners and investors. And 2025, despite the continuing market doldrums, was no exception. If anything, the imperative is greater than […]
The Resurgence of Mental Health Drug Development and Why It Matters
After decades of stagnation, the field of mental health drug development is finally seeing some movement. A wave of innovation, bolstered by new science, shifting public attitudes, and landmark regulatory moments, is transforming how we understand and treat mental health conditions. “It’s like we’ve been playing the same song on repeat,” says Emma Wille, a […]
Spotlight on South Korea: Innovation, Clinical Trials, and Market Trends Shaping 2025
In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into this year’s standout developments and share their outlook for 2025. South Korea has firmly established itself as a global biopharma innovation hub, ranking third worldwide in new drug discoveries. According to Citeline’s Pharmaprojects database, South Korean […]
The ‘Doing Now What Patients Need Next’ Portfolio Approach
Among all the corporate presentations at the 2025 J.P. Morgan Healthcare Conference, one small graphic from Roche (page 7), along with its purpose statement of “Doing now what patients need next”, stood out. The analysis was of how Roche’s product portfolio stacks up against global disease burden, both now and 10 years in the future. […]
Biopharma’s R&D Engine and the Importance of Looking East
One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel showed that 30% of large pharma’s licensing deals now involve a Chinese biotech. This shows the growing interest in partnering in the […]
Spotlight on India: A Booming Part of the Global Ecosystem
In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into last year’s standout developments and share their outlook for 2025. Andrew Warmington, Manufacturing Editor at Citeline, spoke to Anju Ghangurde, Executive Editor, APAC, Citeline, and Vibha Ravi, Senior Editor, APAC, Citeline. How would you describe the […]
Spotlight on Japan: A Supportive Government but Market Share Declines
In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into this year’s standout developments and share their outlook for 2025. Andrew Warmington, Manufacturing Editor at Citeline, spoke to Ian Haydock, Editor-In-Chief, and Lisa Takagi, Managing Editor at Insights in the APAC region, about key developments this […]
Spotlight on China: A Dominant Player in the Clinical Trial Landscape
In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into this year’s standout developments and share their outlook for 2025. China’s booming clinical trial landscape continues to grow and diversify with greater investment from Big Pharma in addition to new promising modalities at play. In our […]
The Practice-Changing Drugs That Will Land in 2025
2025 promises to represent another rich year of progress. A wealth of new therapies are set to successfully graduate from the pipeline. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and most importantly treatments that will meaningfully change how diseases are treated. This article provides a snapshot of […]
Pharma’s Future: More with Less
2023 saw the biopharmaceutical industry spend a record $300bn on R&D activities, reinvesting approximately 30% of prescription revenues to secure the next generation of therapies. Yet, recent weeks have seen falling valuations and stark anecdotes from contract research organizations as their main client base – large pharma companies – have tightened the belt on early […]
